Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Yang Xie, Yan Wang, Shangfei Jiang, Xiaohong Xiang, Jianhua Wang & Linhong Ning. (2022) Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein. Journal of Drug Targeting 30:3, pages 259-268.
Read now
Read now
Madia Lozupone, Vincenzo Solfrizzi, Francesca D’Urso, Ilaria Di Gioia, Rodolfo Sardone, Vittorio Dibello, Roberta Stallone, Angelo Liguori, Chiara Ciritella, Antonio Daniele, Antonello Bellomo, Davide Seripa & Francesco Panza. (2020) Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs 25:3, pages 319-335.
Read now
Read now
Francesco Panza, Davide Seripa, Madia Lozupone, Vincenzo Solfrizzi, Bruno P. Imbimbo, Maria Rosaria Barulli, Rosanna Tortelli, Rosa Capozzo, Paola Bisceglia, Andrea Dimitri, Roberta Stallone, Vittorio Dibello, Nicola Quaranta, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2018) The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy 18:1, pages 25-35.
Read now
Read now
Francesco Panza, Davide Seripa, Vincenzo Solfrizzi, Bruno P. Imbimbo, Madia Lozupone, Antonio Leo, Rodolfo Sardone, Gaetano Gagliardi, Lucia Lofano, Bianca C. Creanza, Paola Bisceglia, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2016) Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opinion on Emerging Drugs 21:4, pages 377-391.
Read now
Read now
Kuniko Kohyama & Yoh Matsumoto. (2015) Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?. ImmunoTargets and Therapy 4, pages 27-34.
Read now
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo & Giancarlo Logroscino. (2014) Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?. Expert Opinion on Biological Therapy 14:10, pages 1465-1476.
Read now
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Michele Giannini, Andrea Santamato, Davide Seripa & Giancarlo Logroscino. (2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 14:9, pages 973-986.
Read now
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Rosanna Tortelli, Andrea Santamato & Giancarlo Logroscino. (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology 10:3, pages 405-419.
Read now
Read now
David B Wang. (2013) Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology. Expert Opinion on Biological Therapy 13:12, pages 1639-1641.
Read now
Read now
Yun Li, Yahong Liu, Zhaojun Wang & Yongjun Jiang. (2013) Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?. Expert Opinion on Biological Therapy 13:11, pages 1515-1522.
Read now
Read now
Articles from other publishers (79)
Mona M. Marzouk, Mai M. Farid, Nesrine M. Hegazi & Shahira M. Ezzat. 2023. Phytochemical Drug Discovery for Central Nervous System Disorders. Phytochemical Drug Discovery for Central Nervous System Disorders
43
80
.
Michael Kunle Ajenikoko, Abayomi Oyeyemi Ajagbe, Oluwanisola Akanji Onigbinde, Akeem Ayodeji Okesina & Ahmad Adekilekun Tijani. (2023) Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction. IBRO Neuroscience Reports 14, pages 64-76.
Crossref
Crossref
Kasper P Kepp, Nikolaos K Robakis, Poul F Høilund-Carlsen, Stefano L Sensi & Bryce Vissel. (2023) The amyloid cascade hypothesis: an updated critical review. Brain.
Crossref
Crossref
Cassandra M. Flynn & Qi Yuan. (2023) Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?. Frontiers in Neuroscience 17.
Crossref
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's
Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Crossref
Heena Shoket & Monika Pandita. 2023. New Horizons in Natural Compound Research. New Horizons in Natural Compound Research
147
166
.
Johra Khan & I. Irem Tatli. 2023. Applications of Stem Cells and derived Exosomes in Neurodegenerative Disorders. Applications of Stem Cells and derived Exosomes in Neurodegenerative Disorders
169
191
.
Afreen Hashmi, Vivek Srivastava, Syed Abul Kalam & Devesh Kumar Mishra. 2022. Alzheimer's Disease. Alzheimer's Disease.
Chuli Song, Tianyu Zhang & Yingjiu Zhang. (2022) Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42. Molecules 27:19, pages 6751.
Crossref
Crossref
Minbiao Ji & Wenlong Yang. 2022. Stimulated Raman Scattering Microscopy. Stimulated Raman Scattering Microscopy
501
514
.
Gustavo Alves Andrade dos Santos. 2022. Pharmacological Treatment of Alzheimer's Disease. Pharmacological Treatment of Alzheimer's Disease
1
14
.
Akhlaq A. Farooqui. 2021. Gut Microbiota in Neurologic and Visceral Diseases. Gut Microbiota in Neurologic and Visceral Diseases
143
158
.
Yi-Shian Peng, Chia-Wei Tang, Yi-Yun Peng, Hung Chang, Chien-Lung Chen, Shu-Lin Guo, Li-Ching Wu, Min-Chang Huang & Hoong-Chien Lee. (2020) Comparative functional genomic analysis of Alzheimer’s affected and naturally aging brains. PeerJ 8, pages e8682.
Crossref
Crossref
Josiane Budni & Jade de Oliveira. 2020. Genetics, Neurology, Behavior, and Diet in Dementia. Genetics, Neurology, Behavior, and Diet in Dementia
865
880
.
M.A. Arya, Maneesha K. Manoj Kumar, M. Sabitha, Krishnakumar N. Menon & Sreeja C. Nair. (2019) Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease. Journal of Drug Delivery Science and Technology 51, pages 297-309.
Crossref
Crossref
Joseph D. Romano & Nicholas P. Tatonetti. (2019) Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives. Frontiers in Genetics 10.
Crossref
Crossref
Ankur A. Patel, Ganepola A.P. Ganepola, John R. Rutledge & David H. Chang. (2019) The Potential Role of Dysregulated miRNAs in Alzheimer’s Disease Pathogenesis and Progression. Journal of Alzheimer's Disease 67:4, pages 1123-1145.
Crossref
Crossref
Yuan Dong, Xiaoheng Li, Jinbo Cheng & Lin Hou. (2019) Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?. International Journal of Molecular Sciences 20:3, pages 558.
Crossref
Crossref
Akhlaq A. Farooqui. 2019. Molecular Mechanisms of Dementia. Molecular Mechanisms of Dementia
73
112
.
Minbiao Ji, Michal ArbelLili ZhangChristian W. FreudigerSteven S. HouDongdong Lin, Xinju YangBrian J. BacskaiX. Sunney Xie. (2018) Label-free imaging of amyloid plaques in Alzheimer’s disease with stimulated Raman scattering microscopy. Science Advances 4:11.
Crossref
Crossref
Qinghui Cheng, Zhi-Wen Hu, Katelynne E. Doherty, Yuto J. Tobin-Miyaji & Wei Qiang. (2018) The on-fibrillation-pathway membrane content leakage and off-fibrillation-pathway lipid mixing induced by 40-residue β-amyloid peptides in biologically relevant model liposomes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1860:9, pages 1670-1680.
Crossref
Crossref
Mingzhen Zhang, Jie Zheng, Ruth Nussinov & Buyong Ma. (2018) Molecular Recognition between Aβ-Specific Single-Domain Antibody and Aβ Misfolded Aggregates. Antibodies 7:3, pages 25.
Crossref
Crossref
Shinya Kusakari, Mikiro Nawa, Katsuko Sudo & Masaaki Matsuoka. (2018) Calmodulin-like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease. Journal of Neurochemistry 144:2, pages 218-233.
Crossref
Crossref
J. Folch, M. Ettcheto, D. Petrov, S. Abad, I. Pedrós, M. Marin, J. Olloquequi & A. Camins. (2018) Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein. Neurología (English Edition) 33:1, pages 47-58.
Crossref
Crossref
J. Folch, M. Ettcheto, D. Petrov, S. Abad, I. Pedrós, M. Marin, J. Olloquequi & A. Camins. (2018) Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurología 33:1, pages 47-58.
Crossref
Crossref
Girdhar Singh Deora, Srinivas Kantham, Stephen Chan, Satish N. Dighe, Suresh K. Veliyath, Gawain McColl, Marie-Odile Parat, Ross P. McGeary & Benjamin P. Ross. (2017) Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimer’s Disease: Synthesis, Pharmacology, and Molecular Modeling Studies. ACS Chemical Neuroscience 8:12, pages 2667-2675.
Crossref
Crossref
Leah K. Cuddy, Claudia Seah, Stephen H. Pasternak & R. Jane Rylett. (2017) Amino-Terminal β-Amyloid Antibody Blocks β-Amyloid-Mediated Inhibition of the High-Affinity Choline Transporter CHT. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Parmi Patel & Jigna Shah. (2017) Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer’s disease: A potential therapeutic target?. Journal of Chemical Neuroanatomy 85, pages 36-42.
Crossref
Crossref
Kasper P. Kepp. (2017) Alzheimer’s disease: How metal ions define β-amyloid function. Coordination Chemistry Reviews 351, pages 127-159.
Crossref
Crossref
Qinghui Cheng & Wei Qiang. (2017) Solid-State-NMR-Structure-Based Inhibitor Design to Achieve Selective Inhibition of the Parallel-in-Register β-Sheet versus Antiparallel Iowa Mutant β-Amyloid Fibrils. The Journal of Physical Chemistry B 121:22, pages 5544-5552.
Crossref
Crossref
Robert A. McArthur. (2017) Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery. Neuroscience & Biobehavioral Reviews 76, pages 4-21.
Crossref
Crossref
Akhlaq A. Farooqui. 2017. Neurochemical Aspects of Alzheimer's Disease. Neurochemical Aspects of Alzheimer's Disease
361
386
.
Akhlaq A. Farooqui. 2017. Neurochemical Aspects of Alzheimer's Disease. Neurochemical Aspects of Alzheimer's Disease
331
359
.
Akhlaq A. Farooqui. 2017. Neurochemical Aspects of Alzheimer's Disease. Neurochemical Aspects of Alzheimer's Disease
1
46
.
Ozgun F. Duzenli & Ayşe Filiz Oner. 2017. Nanotechnology Methods for Neurological Diseases and Brain Tumors. Nanotechnology Methods for Neurological Diseases and Brain Tumors
15
34
.
Seok Rye Choi, Karl Ploessl, Lin Zhu & Hank F. Kung. 2017. Alzheimer’s Disease II. Alzheimer’s Disease II
181
197
.
Yang Liu, Liumi Jiang & Xiaofeng Li. (2016) κ‑carrageenan‑derived pentasaccharide attenuates Aβ25‑35‑induced apoptosis in SH‑SY5Y cells via suppression of the JNK signaling pathway. Molecular Medicine Reports.
Crossref
Crossref
Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Lisa Hua, Prisca Lucas, Scot Styren, Lingfeng Yang, David Li, Ronald S. Black, H. Robert Brashear & Thomas McRae. (2016) Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. Alzheimer's Research & Therapy 8:1.
Crossref
Crossref
Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear & Ronald S. Black. (2016) Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy 8:1.
Crossref
Crossref
Kasper Planeta Kepp. (2016) Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease. Journal of Alzheimer's Disease 55:2, pages 447-457.
Crossref
Crossref
Boaz Levy, Elena Tsoy & Samuel Gable. (2016) Developing Cognitive Markers of Alzheimer’s Disease for Primary Care: Implications for Behavioral and Global Prevention. Journal of Alzheimer's Disease 54:4, pages 1259-1272.
Crossref
Crossref
Jan Aaseth, Jan Alexander, Geir Bjørklund, Knut Hestad, Petr Dusek, Per M. Roos & Urban Alehagen. (2016) Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation. BioMetals 29:5, pages 827-839.
Crossref
Crossref
Kasper P. Kepp. (2016) Alzheimer’s disease due to loss of function: A new synthesis of the available data. Progress in Neurobiology 143, pages 36-60.
Crossref
Crossref
Yuichi Hashimoto, Yuka Toyama, Shinya Kusakari, Mikiro Nawa & Masaaki Matsuoka. (2016) An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling. Journal of Biological Chemistry 291:23, pages 12282-12293.
Crossref
Crossref
David Gelmont, Ronald G. Thomas, Jonathan Britt, Jacqueline A. Dyck‐Jones, Jennifer Doralt, Sandor Fritsch, James B. Brewer, Robert A. Rissman & Paul Aisen. (2016) Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long‐term, placebo‐controlled study of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2:2, pages 131-139.
Crossref
Crossref
Nahla Mahgoub & George S. Alexopoulos. (2016) Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?. The American Journal of Geriatric Psychiatry 24:3, pages 239-247.
Crossref
Crossref
Jaume Folch, Dmitry Petrov, Miren Ettcheto, Sonia Abad, Elena Sánchez-López, M. Luisa García, Jordi Olloquequi, Carlos Beas-Zarate, Carme Auladell & Antoni Camins. (2016) Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment. Neural Plasticity 2016, pages 1-15.
Crossref
Crossref
Miklós Palotai, Gyula Telegdy, Zsolt Bagosi & Miklós Jászberényi. (2016) The action of neuropeptide AF on passive avoidance learning. Involvement of neurotransmitters. Neurobiology of Learning and Memory 127, pages 34-41.
Crossref
Crossref
C.M. Merkley & J.M. Wojtowicz. 2016. Adult Neurogenesis in the Hippocampus. Adult Neurogenesis in the Hippocampus
57
73
.
Thomas A. Bayer & Oliver Wirths. 2016. Immunotherapy and Biomarkers in Neurodegenerative Disorders. Immunotherapy and Biomarkers in Neurodegenerative Disorders
37
50
.
Niels D. Prins. 2016. Immunotherapy and Biomarkers in Neurodegenerative Disorders. Immunotherapy and Biomarkers in Neurodegenerative Disorders
3
17
.
Mark H. Tuszynski & Alan H. Nagahara. 2016. Translational Neuroscience. Translational Neuroscience
33
64
.
Maxime Hallé, Pascale Tribout-Jover, Anne-Marie Lanteigne, Jonathan Boulais, Julien R. St-Jean, Rachel Jodoin, Marie-Pier Girouard, Florin Constantin, Annik Migneault, Frédéric Renaud, Arnaud M. Didierlaurent, Corey P. Mallett, David Burkhart, Anthony Pilorget, Rémi Palmantier & Daniel Larocque. (2015) Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of Immunological Methods 424, pages 64-79.
Crossref
Crossref
Lucie Cahlíková, Daniel I. Pérez, Šárka Štěpánková, Jakub Chlebek, Marcela Šafratová, Anna Hošt’álková & Lubomír Opletal. (2015)
In Vitro Inhibitory Effects of 8-
O
-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood–Brain Barrier
. Journal of Natural Products 78:6, pages 1189-1192.
Crossref
Crossref
Wei Qiang, Mimi Nam & Rumonat D. Akinlolu. 2007. eMagRes. eMagRes
315
322
.
Danica Stanimirovic & Kristin Kemmerich. (2015) Conquering the barriers: are antibody therapeutics feasible for CNS indications?. Future Neurology 10:2, pages 67-70.
Crossref
Crossref
Timothy M. Ryan, Blaine R. Roberts, Gawain McColl, Dominic J. Hare, Philip A. Doble, Qiao-Xin Li, Monica Lind, Anne M. Roberts, Haydyn D. T. Mertens, Nigel Kirby, Chi L. L. Pham, Mark G. Hinds, Paul A. Adlard, Kevin J. Barnham, Cyril C. Curtain & Colin L. Masters. (2015) Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. The Journal of Neuroscience 35:7, pages 2871-2884.
Crossref
Crossref
Jinghong Kou, Junling Yang, Jeong-Eun Lim, Abhinandan Pattanayak, Min Song, Stephanie Planque, Sudhir Paul & Ken-ichiro Fukuchi. (2014) Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease: Prophylactic and Therapeutic Applications. Molecular Neurobiology 51:1, pages 43-56.
Crossref
Crossref
N. Joan Abbott. 2015. Blood‐Brain Barrier in Drug Discovery. Blood‐Brain Barrier in Drug Discovery
567
579
.
Morgan Robinson, Brenda Yasie Lee & Zoya Leonenko. (2015) Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease. AIMS Molecular Science 2:3, pages 332-358.
Crossref
Crossref
Young Hun Lee, Min Cheol Shin, Yong Don Yun, Seo Young Shin, Jong Min Kim, Jeong Moo Seo, Nam-Jung Kim, Jong Hoon Ryu & Yong Sup Lee. (2015) Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry 23:1, pages 231-240.
Crossref
Crossref
Wei Qiang, Rumonat D. Akinlolu, Mimi Nam & Nicolas Shu. (2014) Structural Evolution and Membrane Interaction of the 40-Residue β Amyloid Peptides: Differences in the Initial Proximity between Peptides and the Membrane Bilayer Studied by Solid-State Nuclear Magnetic Resonance Spectroscopy. Biochemistry 53:48, pages 7503-7514.
Crossref
Crossref
Joanna E Pankiewicz, Maitea Guridi, Jungsu Kim, Ayodeji A Asuni, Sandrine Sanchez, Patrick M Sullivan, David M Holtzman & Martin J Sadowski. (2014) Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications 2:1.
Crossref
Crossref
Russell H. Swerdlow, Jeffrey M. Burns & Shaharyar M. Khan. (2014) The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842:8, pages 1219-1231.
Crossref
Crossref
Hui Jin, Weixi Wang, Shanshan Zhao, Weina Yang, Yihua Qian, Ning Jia & Gaifeng Feng. (2014) Aβ-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Aβ deposit in PDAPP mice. Vaccine 32:35, pages 4450-4456.
Crossref
Crossref
Jan Korabecny, Rafael Dolezal, Pavla Cabelova, Anna Horova, Eva Hruba, Jan Ricny, Lukas Sedlacek, Eugenie Nepovimova, Katarina Spilovska, Martin Andrs, Kamil Musilek, Veronika Opletalova, Vendula Sepsova, Daniela Ripova & Kamil Kuca. (2014) 7-MEOTA–donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies. European Journal of Medicinal Chemistry 82, pages 426-438.
Crossref
Crossref
Tanya L. Cupino & Matthew K. Zabel. (2013) Alzheimer’s Silent Partner: Cerebral Amyloid Angiopathy. Translational Stroke Research 5:3, pages 330-337.
Crossref
Crossref
Thomas J. Anastasio. (2014) Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticity. Frontiers in Pharmacology 5.
Crossref
Crossref
Ayodeji A. Asuni, Maitea Guridi, Joanna E. Pankiewicz, Sandrine Sanchez & Martin J. Sadowski. (2014) Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. Annals of Neurology 75:5, pages 684-699.
Crossref
Crossref
Rudy J. Castellani & George Perry. (2014) The complexities of the pathology–pathogenesis relationship in Alzheimer disease. Biochemical Pharmacology 88:4, pages 671-676.
Crossref
Crossref
Seung Ok Nam, Dong Hyun Park, Young Hun Lee, Jong Hoon Ryu & Yong Sup Lee. (2014) Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry 22:4, pages 1262-1267.
Crossref
Crossref
Sophia Schedin-Weiss, Bengt Winblad & Lars O. Tjernberg. (2014) The role of protein glycosylation in Alzheimer disease. FEBS Journal 281:1, pages 46-62.
Crossref
Crossref
Lin Zhu, Karl Ploessl & Hank F. Kung. (2014) PET/SPECT imaging agents for neurodegenerative diseases. Chem. Soc. Rev. 43:19, pages 6683-6691.
Crossref
Crossref
R. Anand, Kiran Dip Gill & Abbas Ali Mahdi. (2014) Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 76, pages 27-50.
Crossref
Crossref
Yu-Hui Liu, Fan Zeng, Ye-Ran Wang, Hua-Dong Zhou, Brian Giunta, Jun Tan & Yan-Jiang Wang. (2013) Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies. Drug Discovery Today 18:23-24, pages 1212-1220.
Crossref
Crossref
Annalena Venneri & Michael F Shanks. (2013) Central effects of cholinesterase inhibitors in Alzheimer’s disease: insights from advanced neuroimaging. Imaging in Medicine 5:5, pages 441-452.
Crossref
Crossref
Patrick L. McGeer & Edith G. McGeer. (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathologica 126:4, pages 479-497.
Crossref
Crossref
Pierre Ousset, Julien Delrieu & Bruno Vellas. (2013) Should interventions to treat or prevent Alzheimer’s disease be tested in a population or as targeted treatment of highly selected study participants?. Alzheimer's Research & Therapy 5:6, pages 62.
Crossref
Crossref
Niels D Prins & Philip Scheltens. (2013) Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research & Therapy 5:6, pages 56.
Crossref
Crossref